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Abstract
Chronic pressure overload due to aortic valve stenosis leads to pathological cardiac hyper-
trophy and heart failure. Hypertrophy is accompanied by an increase in myocyte surface
area, which requires a proportional increase in the number of cell-cell and cell-matrix con-
tacts to withstand enhanced workload. In a proteomic analysis we identified nerve injury-
induced protein 1 (Ninjurin1), a 16kDa transmembrane cell-surface protein involved in cell
adhesion and nerve repair, to be increased in hypertrophic hearts from patients with aortic
stenosis. We hypothesised that Ninjurin1 is involved in myocyte hypertrophy. We analyzed
cardiac biopsies from aortic-stenosis patients and control patients undergoing elective heart
surgery. We studied cardiac hypertrophy in mice after transverse aortic constriction and
angiotensin II infusions, and performed mechanistic analyses in cultured myocytes. We
assessed the physiological role of ninjurin1 in zebrafish during heart and skeletal muscle
development. Ninjurin1 was increased in hearts of aortic stenosis patients, compared to
controls, as well as in hearts from mice with cardiac hypertrophy. Besides the 16kDa Nin-
jurin1 (Ninjurin1-16) we detected a 24kDa variant of Ninjurin1 (Ninjurin1-24), which was pre-
dominantly expressed during myocyte hypertrophy. We disclosed that the higher molecular
weight of Ninjurin1-24 was caused by N-glycosylation. Ninjurin1-16 was contained in the
cytoplasm of myocytes where it colocalized with stress-fibers. In contrast, Ninjurin1-24 was
localized at myocyte membranes. Gain and loss-of-function experiments showed that Nin-
jurin1-24 plays a role in myocyte hypertrophy and myogenic differentiation in vitro. Reduced
levels of ninjurin1 impaired cardiac and skeletal muscle development in zebrafish. We con-
clude that Ninjurin1 contributes to myocyte growth and differentiation, and that these effects
are mainly mediated by N-glycosylated Ninjurin1-24.
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Introduction
Functional adaptation to physiological and pathological stress situations enables muscle to
withstand increased workload [1, 2]. This adaptation involves coordinated development and
growth of myofibers and an increase of contractile proteins eventually leading to hypertrophy
with an enlarged myocyte surface area. To assure a concise and intact tissue composition in
hypertrophy, a proportional increase in the number of cell-cell and cell-matrix contacts medi-
ated by cell-surface proteins is required. Cell-surface proteins are also involved in myogenic
differentiation, because they mediate formation of cell-cell contacts between myoblasts,
which is a prerequisite for myoblast fusion and formation of multinucleated muscle fibers [3].
Despite their importance in myocyte hypertrophy and myogenesis, only few cell-surface pro-
teins involved in muscle growth and differentiation are described. Examples include myo-
maker [4], the only muscle-specific cell-adhesion molecule, intercellular adhesion molecule-1
(ICAM-1) [5], and neuronal cell-adhesion molecule (NCAM) [6]. We used a proteomics based
approach and identified the cell-adhesion molecule nerve injury-induced protein 1 (Nin-
jurin1), described as two-pass transmembrane cell-surface protein [7], to be increased in the
myocardium of patients with severe aortic stenosis, suggesting a role of Ninjurin1 in patholog-
ical cardiac hypertrophy. Ninjurin1 is ubiquitously expressed, and conserved from fruit fly to
man [8–10]. It was primarily studied in the peripheral nervous system where Ninjurin1 is up-
regulated in Schwann cells and neurons after nerve injury and mediates repair processes [7, 8].
By homophilic interaction, Ninjurin1 mediates the contact between macrophages and vascular
endothelial cells [11], and enables myeloid cells to migrate through the blood brain barrier in
experimental autoimmune encephalomyelitis [12, 13]. Accordingly, germ-line deletion of Nin-
jurin1 reduced migration of macrophages into the brain and attenuated disease activity in
mice with experimental autoimmune encephalomyelitis [14]. Of note, N-glycosylation was
shown to be important for Ninjurin1 homomer assembly [15]. Although, the function of Nin-
jurin1 in nervous tissue and in myeloid cells is well understood, the biological relevance of
Ninjurin1 in heart and skeletal muscle has not been characterized. However, the strong induc-
tion of Ninjurin1 as a cell-surface transmembrane protein in the hypertrophic myocardium
and its ability to form homomers that mediate cell-cell contacts led us to hypothesize that Nin-
jurin1 is involved in myocyte hypertrophy and myogenic differentiation. We used heart tissue
from patients and mice with pathological cardiac hypertrophy, and performed mechanistic
analyses in cultivated myocytes and zebrafish to test this hypothesis. We found increased Nin-
jurin1 protein contents in hypertrophic hearts from patients and mice. Our in vitro and in vivo
experiments demonstrate that Ninjurin1 is involved myocyte growth and differentiation, and
that these effects are mainly mediated by N-glycosylated Ninjurin1-24. In summary, our data
indicate a role of Ninjurin1 in myocyte stress response.
Methods
Patients with aortic stenosis and donor hearts
Written informed consent was obtained from all aortic stenosis patients prior to surgery and
inclusion in the study, and the study was approved by the ethical committee of Charite´ Univer-
sita¨tsmedizin Berlin. Myocardial biopsy samples of the left ventricle from nine patients with
aortic stenosis were obtained during cardiac surgery. Human non-diseased myocardial tissue
was collected from six general organ donors whose hearts were not used for transplantation
due to logistical reasons. Sample collection and the experimental protocols were approved by
the Ethical Review Board of the Medical Center of the University of Szeged and by the Scien-
tific and Research Ethical Committee of the Medical Scientific Board at the Hungarian
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Ministry of Health (ETT-TUKEB; No.: 51-57/1997 OEj and 4991-0/2010-1018EKU). The
cause of death in general donors included accidents, traumatic cerebral injuries, subarachnoid
hemorrhage, subdural hematoma and cerebral aneurism rupture. Tissue samples were frozen
in liquid nitrogen immediately after collection and stored at -80˚C.
Animal models of cardiac hypertrophy
All animal procedures were performed in accordance with the guidelines of Charite´ Universi-
ta¨tsmedizin Berlin as well as Max-Delbru¨ck Center for Molecular Medicine and were approved
by the Landesamt fu¨r Gesundheit und Soziales (LaGeSo, Berlin, Germany) for the use of labo-
ratory animals (permit numbers: G 0229/11, G 0084/05, IC 114-ZH130) and followed the
‘Principles of Laboratory Animal Care’ (NIH publication no. 86–23, revised 1985) as well as
the current version of German Law on the Protection of Animals.
Thoracic aortic banding (TAC). Nine to ten week-old male C57BL/6J mice (purchased
from Harlan Winkelmann (Netherlands)) were subjected to pressure overload by 27G thoracic
aortic constriction (TAC, n = 5) for 2 weeks as described [16, 17]. The mice were anesthetized
with ketamine hydrochloride (80 mg/ml)/xylazine hydrochloride (12 mg/ml) solution admin-
istered by intraperitoneal injection at a dose of 1 mg/kg. Animals were placed in supine posi-
tion under a dissecting stereoscope. Following anesthesia, mice were intubated and artificially
ventilated (respirator: Hugo Basile model 7025; FMI). After sternotomy, the aorta and carotid
arteries were exposed, and the transverse aorta was constricted by tying a 6–0 silk suture (FST)
against a 27-gauge needle. The needle was then removed, leaving a narrowing of 0.4 mm in
aortic diameter. A sham procedure in which the thoracic aorta was not banded was performed
in littermates for comparison (sham, n = 5). Animals recovered from anesthesia under warm-
ing conditions and normal ventilation. As analgesia, carprofen was administered to TAC- and
sham-operated mice subcutaneously prior to surgery (10mg/kgKG) and following surgery
(every 24 hours for 4 days; 5mg/kgKG).
Angiotensin II delivery. Angiotensin (Ang) II (3.0 mg / kg BW / day, human) dissolved
in 150 mM NaCl and 1 mM acetic acid was delivered chronically to 12-week-old male C57BL/
6J mice (purchased from Charles River, Sulzfeld, Germany) (n = 8) for fourteen days by an
implanted osmotic mini-pump (ALZET model 2002) as described previously [17–19]. For
control 12-wk-old male C57BL/6J mice (vehicle, n = 5) underwent the same procedure except
that the pumps were only loaded with vehicle (150 mM NaCl, 1 mM acetic acid). All mice
were anesthetized with isoflurane. As analgesia, carprofen was administered once to all mice
by subcutaneous injection (5mg/kgKG) prior to surgery.
All animals were housed under standard conditions with a 12 hour light-dark cycle and
controlled temperature (21˚C) regime. Water and food were provided ad libitum. Environ-
mental enrichment (shelter and nesting material) was provided to all animals throughout the
experiments. Post-operatively the health status of all animals was monitored at least once daily
in order to assess animal health and well-being. The criteria used to judge animal health and
well-being were based on a predefined checklist and included, beside others, the assessment of
animal behavior, fur texture, respiration, changes in movement, apathy, injuries, pain, and
changes in body weight. At the end of the respective experiment mice were sacrificed by cervi-
cal dislocation; hearts were isolated, and heart weight, body weight, and tibia length were
measured.
For detailed information about zebrafish experiments, BD Pharmingen PowerBlot, cell cul-
ture, isolation of neonatal rat ventricular myocytes, transfection of cDNA expression plasmids
and small interfering RNA (siRNA), cycloheximide chase assay, tunicamycin treatment, pro-
tein extraction and Western blot analysis, biochemical fractionation of cells, RNA isolation,
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cDNA synthesis, quantitative RT-PCR (qRT-PCR), immunocytochemistry and immunohistol-
ogy, please refer to the S1 File.
Statistics
Data are presented as mean ± standard deviation (SD) unless otherwise stated. A non-paramet-
ric test, the Mann-Whitney test, was performed to analyze group differences for patient sam-
ples. Student’s t-tests and one-way ANOVA analyses were used for animal experiments, PCR
data and cell culture experiments. P< 0.05 was considered as statistically significant.
Results
Ninjurin1 is increased in hearts of patients with severe aortic stenosis
To identify proteins regulated in left ventricular hypertrophy (LVH) due to severe aortic steno-
sis (AS) in humans, proteins extracted from left ventricular biopsy samples of patients under-
going elective aortic valve replacement surgery (n = 9) and from donor hearts (n = 6) were
subjected to the BD Pharmingen PowerBlot system and analyzed for differences in protein
contents. Patient characteristics are shown in S1 Table. The transmembrane cell adhesion mol-
ecule Ninjurin1 was highly expressed in the myocardium of AS patients but not in control
samples. Immunohistochemistry with anti-Ninjurin1 antibody on cryosections from left ven-
tricular biopsies of AS patients and donors confirmed that Ninjurin1 was increased in AS com-
pared to donor myocardium (Fig 1A). Western blot experiments on proteins isolated from
representative biopsies of the left ventricle of AS patients (n = 3) and donors (n = 3) with anti-
Ninjurin1 antibody verified the results from the PowerBlot analysis (Fig 1B). Western blot
analysis from a larger cohort of AS patients (n = 9) and donors (n = 6) confirmed these find-
ings (S1 Fig). A Ninjurin1 specific signal at 24kDa (Ninjurin1-24) was detected in AS samples
only but not in controls, whereas the 16kDa Ninjurin1 variant (Ninjurin1-16) was expressed at
low levels in both groups (Fig 1B). To investigate the expression pattern of Ninjurin1 and to
determine the tissue distribution of both Ninjurin1 variants we performed qRT-PCR and
Western blot analysis in heart and skeletal muscle samples, and compared it to non-muscle tis-
sue. We found that Ninjurin1 mRNA was ubiquitously expressed and that its expression in
muscle is comparable to non-muscle tissue (Fig 1C). Likewise, Western blot analysis of
protein lysates from different mouse tissues showed that Ninjurin1 protein was ubiquitously
expressed. However, expression levels and the ratio of Ninjurin1-16 to Ninjurin1-24 differed
between the tissues investigated, as also shown by densitometrical analysis (Fig 1D). Since,
Ninjurin1 is a transmembrane cell-surface protein [7] and N-glycosylation is a hallmark of cell
membrane proteins [20] together with a recent report that Ninjurin1 is N-glycosylated [15] we
reasoned that the molecular weight difference between Ninjurin1-16 and Ninjurin1-24 was
due to its N-glycosylation. To test this hypothesis we investigated N-glycosylation of Ninjurin1
in H9c2 cells. H9c2 cells are an immortalized cell line originally derived from embryonic rat
ventricular tissue [21] that shows a cardiac phenotype and are used to investigate mechanisms
of cardiomyocyte stress response [22, 23]. Because NRVM and H9c2 cells were shown to
respond similar to hypertrophic stimuli [24–28] we used both models in our study. We treated
H9c2 cells, which were differentiated for two and three days (MT2, MT3), respectively, with
the N-glycosylation inhibitor tunicamycin. Western blot analysis and subsequent densitometry
showed that these cells contained both Ninjurin1-16 and Ninjurin1-24. Tunicamycin abol-
ished the formation of Ninjurin1-24 (Fig 1E and 1F), indicating that the observed molecular
weight difference between Ninjurin1-16 and Ninjurin1-24 was caused by N-glycosylation of
Ninjurin1. As a control, we used tunicamycin to inhibit N-glycosylation of the cell surface
receptor glycoprotein 130 (gp130) (Fig 1E).
Ninjurin 1 and muscle growth
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Fig 1. Ninjurin1 is increased in hypertrophic left ventricle of patients with severe aortic stenosis. (A) Immunofluorescent staining of cryosections from biopsy
specimen of two AS (AS_a, AS_b) and two donor (control_a, control_b) hearts with anti-Ninjurin1 as primary antibody and Alexa Fluor 555 conjugated secondary
antibody. Nuclei were stained with DAPI (blue). MW, molecular weight; kDa, kilo Dalton. Scale bar, 75 μm. (B) Western blots of proteins isolated from left ventricular
tissue of patients with severe aortic stenosis (AS) undergoing elective aortic valve replacement surgery (n = 3) and donor hearts (n = 3) using anti-Ninjurin1 antibody.
GAPDH was used as loading control. The Ninjurin1 isoforms at 16kDa (Ninjurin1-16) and 24kDa (Ninjurin1-24) are differentially expressed therefore the
membranes underwent short and long exposure, indicated by short exp. and long exp., respectively. (C) Quantitative RT-PCR analysis of Ninjurin1 (Ninj1) in different
mouse tissues obtained from untreated C57BL/6J mice as indicated (n = 3). 18S ribosomal RNA expression was used as reference. Data are presented as mean ± SD.
(D) Representative immunoblot of proteins isolated from different mouse tissues using anti-Ninjurin1 antibody. GAPDH was used as loading control. The Ninjurin1
Ninjurin 1 and muscle growth
PLOS ONE | https://doi.org/10.1371/journal.pone.0216987 May 15, 2019 5 / 22
To investigate if increased Ninjurin1 expression is a general feature for LVH and if this phe-
nomenon is conserved throughout species, we analyzed the hearts of two standard mouse
models of pathological LVH. First, transverse-aortic constriction (TAC, n = 5) and sham
(n = 5) operations were performed in wild type mice, and hearts were analyzed two weeks after
surgery. As expected, TAC induced LVH as shown by an increase in heart-weight-to-tibia
length ratio and increased thickness of the interventricular septum and left ventricular poste-
rior wall during diastole measured by transthoracic echocardiography (S2 Table). Likewise,
qRT-PCR on RNA isolated from left ventricular tissue showed an increased atrial natriuretic
peptide (Nppa) and B-type natriuretic peptide (Nppb) gene expression in TAC compared to
sham mice (Fig 2A). Western blot analysis and subsequent densitometry showed an increased
Ninjurin1 protein content (Ninjurin1-16 and Ninjurin1-24) in hearts of TAC (n = 5) com-
pared to sham (n = 5) animals (Fig 2B and 2C). We also tested Ninjurin1 regulation in
response to continuous administration of Angiotensin II (Ang II) via osmotic mini-pumps to
mice that also causes LVH. As expected, two weeks of Ang II treatment resulted in LVH, as
demonstrated by an increase in heart-weight-to-tibia length ratio (S3 Table), and increased left
ventricular Nppa and Nppb gene expression (Fig 2D). Western blot analysis and subsequent
densitometry showed that both Ninjurin1 variants were increased in hearts of Ang II (n = 8)
treated mice compared to vehicle treated controls (n = 4) (Fig 2E and 2F). In summary, upre-
gulation of Ninjurin1 accompanies pathological cardiac hypertrophy in both AS patients and
animal models of pathological cardiac hypertrophy.
Reduction of Ninjurin1 inhibits cardiomyocyte hypertrophy in vitro
We next investigated if Ninjurin1 is contained in cardiomyocytes and if it plays a role in cardi-
omyocyte hypertrophy. Immunocytochemistry confirmed that endogenous Ninjurin1 protein
was contained in NRVM (Fig 3A). Treatment of NRVM with the hypertrophy inducing com-
pounds phenylephrine (100 μM) and endothelin 1 (50 nM) increased the amount of Ninjurin1
protein in NRVM. Western blot analyses and densitometry revealed that phenylephrine and
endothelin 1 treatment caused an increase of Ninjurin1-24 but not Ninjurin1-16 (Fig 3B and
3C). To investigate if Ninjurin1 is important for cardiomyocyte hypertrophy we used siRNA
to reduce Ninjurin1 expression in NRVM and compared them to cells treated with scrambled
siRNA controls (Fig 3D). As expected and as shown by qRT-PCR, phenylephrin and endothe-
lin 1 caused an increase in Nppb and a decrease in α-Mhc mRNA expression in control siRNA
treated NRVM (Fig 3E). However, knockdown of Ninjurin1 decreased phenylephrine- and
endothelin 1-induced Nppb mRNA expression compared to controls (Fig 3E). Likewise, Nin-
jurin1 knockdown abolished phenylephrine- and endothelin 1-mediated reduction of a-Mhc
mRNA expression (Fig 3E).
To substantiate our findings we investigated the role of Ninjurin1 in H9c2 cells. Using
immunocytochemistry, we found that Ninjurin1 was contained in H9c2 cells (Fig 4A). We
next treated H9c2 myocytes with arginine-vasopressin (AVP), known to induce hypertrophy
of these cells [29]. Western blot analysis showed that AVP increased Ninjurin1-16 and Nin-
jurin1-24, as well as fast Myosin protein in H9c2 cells (Fig 4B). To investigate if Ninjurin1 is
important for hypertrophy, we used siRNA to reduce Ninjurin1 expression in H9c2 cells and
isoforms at 16kDa (Ninjurin1-16) and 24kDa (Ninjurin1-24) are indicated. Graph: Densitometric analysis of (B). The total Ninjurin1 content (Ninjurin1-16 plus
Ninjurin1-24) per tissue was set as 100% and the relative amount of Ninjurin1-16 and Ninjurin1-24, respectively, was related to that. GP indicates gastrocnemius /
plantaris; TA, tibialis anterior; Sol, soleus; EDL, extensor digitorum longus. (E) Western blots of proteins isolated from 2 days (MT2) or 3 days (MT3) differentiated
H9c2 cells, treated with 1μg/ml Tunicamycin or vehicle (1 mg/ml dimethylsulfoxide) for 48 h, as indicated. Detection of Ninjurin1 and glycoprotein 130 (gp130) using
specific antibodies. Tubulin was used as loading control. (F) Densitometric analysis of (E); data are presented as mean ± SD. � P = 0.05; ��� P< 0.001. A two-tailed,
unpaired Student’s t-test was used to calculate the P values.
https://doi.org/10.1371/journal.pone.0216987.g001
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Fig 2. Ninjurin1 expression increases in the left ventricle of mice with pathological left ventricular hypertrophy. (A) Quantitative RT-PCR analysis of atrial
(Nppa) and B-type natriuretic peptide (Nppb) on RNA from left ventricular tissue of 9- to 10-wk-old male mice subjected to two weeks of transverse aortic
constriction (TAC) (n = 5) or sham surgery (n = 5). Glyceraldehyde-3 phosphate dehydrogenase (GAPDH) expression was used as reference. Data are presented
as mean ± SD. � P< 0.05. (B) Immunoblots of proteins isolated from left ventricles of mice subjected to sham (n = 5) or TAC (n = 5) surgery using anti-
Ninjurin1 antibody. GAPDH was used as loading control. The Ninjurin1 isoforms at 16kDa (Ninjurin1-16) and 24kDa (Ninjurin1-24) are differentially
expressed, therefore the membranes underwent short (short exp.) and long exposure (long exp.), respectively. (C) Densitometric analysis of (B); data are
presented as mean ± SEM. � P< 0.05. (D) Quantitative RT-PCR analysis of Nppa and Nppb on RNA from left ventricular tissue of 12-wk-old male mice
subjected to chronic Angiotensin II (Ang II, n = 8) or vehicle (n = 4) infusion, respectively, via osmotic mini-pumps for two weeks. GAPDH expression was used
as reference. Data are presented as mean ± SD. ��� P< 0.001. (E) Immunoblots of proteins isolated from left ventricles of mice subjected to vehicle (n = 4) or
Ang II (n = 8) treatment using anti-Ninjurin1 antibody. GAPDH was used as loading control. (F) Densitometric analysis of (E); data are presented as
mean ± SEM. �� P< 0.01. A two-tailed, unpaired Student’s t-test was used to calculate the P values.
https://doi.org/10.1371/journal.pone.0216987.g002
Ninjurin 1 and muscle growth
PLOS ONE | https://doi.org/10.1371/journal.pone.0216987 May 15, 2019 7 / 22
Fig 3. Knockdown of Ninjurin1 by siRNA impairs cardiomyocyte hypertrophy in vitro. (A) Immunofluorescent staining of NRVM treated with
vehicle, phenylephrine (100 μM) and endothelin 1 (50 nM) with anti-Ninjurin1 as primary antibody and Alexa Fluor 488 conjugated secondary
antibody (green). Nuclei were stained with DAPI (blue). Scale bar, 75 μm. (B) Immunoblots (left) and densitometric analysis (right) of proteins
isolated from vehicle, phenylephrine (100 μM) and endothelin 1 (50 nM) treated NRVM using anti-Ninjurin1 antibody. GAPDH was used as loading
control. The 16kDa (Ninjurin1-16) and 24kDa (Ninjurin1-24) Ninjurin1 isoforms are indicated. (C) Densitometric analysis of the Ninjurin1-24 signal
Ninjurin 1 and muscle growth
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from (B). (D, E) NRVM were transfected with control siRNA (control_siRNA) (n = 3) or siRNA targeting Ninjurin1 (Ninjurin1_siRNA) (n = 3). (D)
Quantitative RT-PCR analysis of Ninjurin1 (Ninj1). GAPDH expression was used as reference. Data are presented as mean ± SD. � P< 0.05. (E)
Quantitative RT-PCR analysis of Nppb and alpha-myosin heavy chain 1 (α-Mhc). GAPDH expression was used as reference. Data are presented as
mean ± SD. � P< 0.05, �� P< 0.01, ��� P< 0.001.
https://doi.org/10.1371/journal.pone.0216987.g003
Fig 4. Knockdown of Ninjurin1 by siRNA leads to impaired cardiomyocyte hypertrophy in vitro. (A) Immunofluorescent staining of H9c2 myocytes with anti-
Ninjurin1 as primary antibody and Alexa Fluor 488 conjugated secondary antibody (green). Nuclei were stained with DAPI (blue). Scale bar, 75 μm. (B) Hypertrophy
of 7 days differentiated H9c2 myotubes was induced by arginine-vasopressin (AVP) treatment for 24 hours. Non-treated cells were used as control. Immunoblots of
proteins isolated from H9c2 myotubes (as indicated) using anti-Ninjurin1 and anti-fast myosin antibody. GAPDH was used as loading control. The 16kDa (Ninjurin1-
16) and 24kDa (Ninjurin1-24) Ninjurin1 isoforms are indicated. (C-E) 7 days differentiated H9c2 myotubes were transfected with control siRNA (control_siRNA)
(n = 6) or siRNA targeting Ninjurin1 (Ninjurin1_siRNA) (n = 6). 48 hours after transfection hypertrophy was induced by AVP treatment for 24 hours (n = 3). Non-
treated cells were used as control (n = 3). (C) Quantitative RT-PCR analysis of Ninjurin1 (Ninj1), Nppb and Myosin heavy chain 1 (Myh1). GAPDH expression was
used as reference. Data are presented as mean ± SD. � P< 0.05, �� P< 0.01, ��� P< 0.001(D) Immunoblots of proteins isolated from H9c2 myotubes (as indicated)
using anti-Ninjurin1 and anti-fast myosin antibody. GAPDH was used as loading control. The 16kDa (Ninjurin1-16) and 24kDa (Ninjurin1-24) Ninjurin1 isoforms
are indicated. (E) Densitometric analysis of fast myosin protein content from (D). Data are presented as mean ± SD. � P< 0.05, �� P< 0.01. MW, molecular weight;
kDa, kilo Dalton. A two-tailed, unpaired Student’s t-test was used to calculate the P values.
https://doi.org/10.1371/journal.pone.0216987.g004
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compared them to cells treated with scrambled siRNA controls. As shown by qRT-PCR knock-
down of Ninjurin1 decreased AVP induced Nppb and Myh1 mRNA expression compared to
controls (Fig 4C). Western blotting and its densitometry showed that reduction of Ninjurin1
decreased the ability of AVP to increase the myosin protein content (Fig 4D and 4E). In sum-
mary, our data indicate that Ninjurin1 plays a role in cardiomyocyte hypertrophy in vitro.
Ninjurin1 expression is increased during myogenic differentiation
Our data showed that Ninjurin1 was not only expressed in the heart but also in skeletal muscle
(Fig 1C and 1D). They also showed that skeletal muscle contained Ninjurin1-16 as well as Nin-
jurin1-24 (Fig 1C and 1D). Importantly, Ninjurin1-24 which increases in LVH was exclusively
expressed in differentiated skeletal myotubes (Fig 5). Therefore, we hypothesized that Nin-
jurin1 does not only play a role in cardiomyocyte hypertrophy but also in skeletal myocyte
growth and differentiation. Using immunocytochemistry, we confirmed that endogenous Nin-
jurin1 protein was contained in C2C12 myoblasts (Fig 5A) and that its immunoreactivity
steadily increased during differentiation of C2C12 myoblasts to myotubes (Fig 5A). Western
blot analysis revealed that Ninjurin1-16 was contained in myoblasts as well as in myotubes as
well as in non-myocyte cell lines (Fig 5B). In contrast, N-glycosylated Ninjurin1 (Ninjurin1-
24) was exclusively detectable in differentiated myotubes (Fig 5B). To investigate the kinetics
of Ninjurin1s N-glycosylation during myogenic differentiation we performed Western blot
analyses of lysates from myoblasts and myotubes at different stages of differentiation in C2C12
cells. N-glycosylated Ninjurin1 (Ninjurin1-24) was first detected after 48 hours of differentia-
tion, and its expression gradually increased during differentiation until day 5 when it reached
a steady state (Fig 5C). In contrast, Ninjurin1-16 was already present in myoblasts and its
amount did not change during differentiation. To test if myotube atrophy has an effect on Nin-
jurin1 we treated differentiated C2C12 myotubes with the glucocorticosteroid dexamethasone
(Dexa), an established atrophy inducer. Western blot analysis showed a reduction particularly
of the Ninjurin1-24 protein content in C2C12 myotubes after 24 hours and 48 hours of Dexa-
treatment (Fig 5C). In summary, our data implicate that N-glycosylated Ninjurin1 (Ninjurin1-
24) plays a role in myogenic differentiation.
We further investigated the subcellular localization of Ninjurin1-16 and Ninjurin1-24. By
immunocytochemistry of myoblasts, which do not contain Ninjurin1-24, we found that Nin-
jurin1-16 was co-localized with actinin-containing structures that are important for migration
(S2A Fig). Neither Ninjurin1-16 nor Ninjurin1-24 was colocalized with GAPDH, which was
used as a marker for soluble cytosolic proteins (S2B Fig). Because N-glycosylation of proteins
can affect their intracellular trafficking, we performed biochemical fractionation of myoblasts
and myotubes to investigate if Ninjurin1-16 and Ninjurin1-24 localize to different intracellular
compartments. Indeed, both Ninjurin1 variants were located to different subcellular compart-
ments; whereas, Ninjurin1-24 was enriched in membrane containing fractions, Ninjurin1-16
co-precipitated with vesicles (S2C Fig). In summary, the different expression patterns, differ-
entiation dependent N-glycosylation and divergent cellular distribution point towards specific
functions of Ninjurin1-16 and Ninjurin1-24 in myocytes.
Ninjurin1 contributes to myogenic differentiation in vitro
Since Ninjurin1 expression increased during myogenic differentiation, we reasoned that Nin-
jurin1 is involved in this process. We used siRNA to reduce endogenous Ninjurin1 in myo-
blasts and investigated its effect on differentiation. We used qRT-PCR and Western blot
analysis to quantify Myh gene expression and protein content as late markers for myogenic
differentiation [30]. qRT-PCR showed the expected increase in Myh1, 2, 4 and 7 gene
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Fig 5. Ninjurin1 increases during myogenic differentiation in skeletal myocytes. (A) Immunofluorescent staining
of C2C12 myoblasts, and for 3, 6 and 8 days differentiated myotubes, as indicated (MT3, MT6, MT8), with anti-
Ninjurin1 as primary antibody and Alexa Fluor 488 conjugated secondary antibody (green). Nuclei were stained with
DAPI (blue). Scale bar, 75 μm. (B) Western blots of proteins isolated from different non-myocyte (BNLCL2, HEK-293,
MCF-7, HeLa, Cos-7, THP-1) and myocyte (C2C12, H9c2, CHQ) cell lines (as indicated) using anti-Ninjurin1
Ninjurin 1 and muscle growth
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expression after seven days of differentiation. The increase in Myh1, 4 and 7 gene expression
was significantly diminished by Ninjurin1 siRNA (Fig 6A). Western blot analysis showed that
knockdown of Ninjurin1 led to a decrease of both fast-myosin and slow-myosin protein after
three and five days of differentiation (Fig 6B). Microscopical analysis showed that knockdown
of Ninjurin1 abolished myotube formation after three and five days of differentiation com-
pared to controls (Fig 6C). Because Western blot analysis showed that Ninjurin1 siRNA treat-
ment only diminished Ninjurin1-24 but not Ninjurin1-16 protein after 3 days, 5 days and 7
days of differentiation (Fig 6B) we hypothesized that the half-life of Ninjurin1-16 is longer
than that of Ninjurin1-24. Therefore, we tested the stability of the Ninjurin1 variants using
cycloheximide decay assays and used the proteasome inhibitor MG132 to determine if protein
degradation was proteasome dependent. The assays were controlled by determination of Herp
and Myogenin protein contents, which are degraded in a proteasome dependent and indepen-
dent manner, respectively. We found that N-glycosylated Ninjurin1 (Ninjurin1-24) was
degraded within 8 hours and that its degradation was not dependent on the proteasome. In
contrast, Ninjurin1-16 was not degraded throughout the duration of the experiment indicating
that Ninjurin1-16 is highly stable (Fig 6D).
Because knockdown of Ninjurin1 inhibited myogenic differentiation, we reasoned that ele-
vated Ninjurin1 levels would accelerate this process. We therefore overexpressed FLAG-tagged
Ninjurin1 in C2C12 myoblasts, differentiated them for 3 days, 5 days and 7 days and investi-
gated markers of myogenic differentiation. Western blot analysis using anti-FLAG antibody
confirmed effective Ninjurin1 overexpression (S3A Fig). As expected, all tested Myh genes sig-
nificantly increased after three, five and seven days of differentiation compared to myoblasts
(S3B Fig). Importantly, compared to empty vector control Ninjurin1 overexpression resulted
in an increased Myh1 expression throughout differentiation. Ninjurin1 overexpression also
increased Myh2 expression, at days 3 and 7 of differentiation, Myh4 expression, at days 3 and 5
of differentiation, and Myh7 expression at differentiation day 3 (S3B Fig). Western blotting
showed that Ninjurin1 overexpression increased fast-myosin protein contents at day 5 and 7
of differentiation. However, Ninjurin1 overexpression had no effect on slow myosin protein
content (S3A Fig). In concert, our loss- and gain-of-function data show that Ninjurin1 con-
tributes to myogenic differentiation.
Ninjurin1 depletion in zebrafish results in impaired heart and skeletal
muscle development
To assess the role of Ninjurin1 in vivo, we turned to the well-established zebrafish model. We
used either CRISPR/Cas9 genome editing [31, 32] to create targeted mutations in the ninjurin1
gene or morpholino oligonucleotide-mediated knockdown to assess the functional role of Nin-
jurin1 in muscle development. While uninjected and Cas9-control injected embryos displayed
a normal morphology, the loss of ninjurin1 induced by either ninjurin1 sgRNA/Cas9 somatic
mutagenesis (ninj1 sgRNA) or by morpholino-mediated knockdown (ninj1e2i2 MO) lead to
body axis and cardiac defects manifested as shorter body length and cardiac edema, respec-
tively (Fig 7A and 7B), indicating impaired heart and skeletal muscle development. To validate
antibody. The myocyte cell lines C2C12, H9c2 and CHQ were analyzed as undifferentiated myoblasts (-) and
differentiated myotubes (+). GAPDH was used as loading control. The 16kDa (Ninjurin1-16) and 24kDa (Ninjurin1-
24) Ninjurin1 variants are indicated. (C) Western blots of proteins isolated from C2C12 myoblasts and for different
time points (as indicated) differentiated myotubes using anti-Ninjurin1 antibody. To induce atrophy 9 days
differentiated C2C12 myotubes were treated with Dexamethasone (10 μM) for 1 and 2 days, as indicated. GAPDH was
used as loading control. The 16kDa (Ninjurin1-16) and 24kDa (Ninjurin1-24) Ninjurin1 isoforms are indicated. MHC
indicates myosin heavy chain.
https://doi.org/10.1371/journal.pone.0216987.g005
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Fig 6. Knockdown of Ninjurin1 impairs myogenic differentiation. C2C12 myoblasts were transfected with control siRNA (control_siRNA) or siRNA targeting
Ninjurin1 (Ninjurin1_siRNA). Differentiation was initiated 24 hours after transfection. (A) RNA was isolated from C2C12 myoblasts and after 7 days of differentiation
(MT7). Quantitative RT-PCR analysis of myosin heavy chain (Myh) 1, 2, 4 and 7 is shown. Glyceraldehyde-3 phosphate dehydrogenase (GAPDH) expression was used
as reference. Data are presented as mean ± SD. A two-tailed, unpaired Student’s t-test was used to calculate the P values. � P< 0.05, �� P< 0.01, ��� P< 0.001. n = 3.
(B) Western blots of proteins isolated from C2C12 myoblasts, and for 3, 5 and 7 days differentiated myotubes, as indicated (MT3, MT5, MT7), with anti-Ninjurin1,
slow myosin and anti-fast myosin antibody (as indicated). GAPDH was used as loading control. The Ninjurin1 isoforms at 16kDa (Ninjurin1-16) and 24kDa
(Ninjurin1-24) are differentially expressed, therefore the membranes underwent short and long exposure, indicated by short exp. and long exp., respectively. The
16kDa (Ninjurin1-16) and 24kDa (Ninjurin1-24) Ninjurin1 isoforms are indicated. (C) Microscopy pictures of differentiated C2C12 myocytes at day 3 (MT3) and 5
(MT5) of differentiation following transfection with control siRNA (control_siRNA) and siRNA targeting Ninjurin1 (Ninjurin1_siRNA), respectively. Scale bar,
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the gene-specific effects of both knock-down technologies, we amplified the splicing products
formed in uninjected, control morpholino-injected (control MO), and ninj1e2i2 MO-injected
embryos. Our results showed splicing defects specific to ninj1e2i2 MO (Fig 7C). DNA sequenc-
ing of the ninjurin1 sgRNA targeted region of the ninjurin1 gene revealed various mutations at
the cut site, with deletions ranging from two to twenty-two base pairs (Fig 7D). qRT-PCR
showed a significant reduction in ninjurin1 expression in ninj1 sgRNA-Cas9-injected but not
in Cas9-injected embryos (Fig 7E). To assess the heart morphology in more detail, we reduced
ninjurin1 levels in the transgenic zebrafish reporter line Tg(myl7:EGFP)twu34 expressing
enhanced green fluorescent protein (EGFP) specifically in cardiomyocytes [33]. The most sig-
nificant findings we observed were defects in cardiac looping with increased frequency of right
sided hearts, so called dextrocardia (Fig 7F and 7G), whereas heart rate was not affected (Fig
7H). The profound body axis defects prompted us to examine skeletal muscle morphology.
The skeletal muscle cells in ninj1e2i2 MO embryos formed shorter somites, which was associ-
ated with the loss of the typical chevron shape (Fig 7I and 7J). Moreover, the myosin heavy
chain protein that normally assembles within the sarcomeres appeared aggregated, especially
in the apical regions of the myocytes in ninj1e2i2 MO embryos when compared to uninjected
controls (Fig 7I, insets). All together, these phenotypes indicate that Ninjurin1 plays an impor-
tant role in heart and skeletal muscle development in zebrafish embryos.
Discussion
We identified Ninjurin1 as potential regulator of myocyte hypertrophy and myogenic differen-
tiation. Ninjurin1 expression was increased in pathological cardiac hypertrophy of man and
mice in vivo and cardiomyocytes in vitro. Knockdown of Ninjurin1 inhibited agonist-induced
cardiomyocyte hypertrophy. Also, deletion of Ninjurin1 led to defects in cardiac looping, dex-
trocardia, and skeletal muscle formation in zebrafish. These cardiac development and myogen-
esis phenotypes could be related to Ninjurin1‘s effects on myogenic differentiation, which was
increased by Ninjurin1 overexpression and diminished by its knockdown. In muscle, Nin-
jurin1 occurred as a 16kDa (Ninjurin1-16) and a 24kDa (Ninjurin1-24) variant. While myo-
blasts only contained Ninjurin1-16 which was associated with stress fibers, differentiated
myotubes additionally contained the N-glycosylated Ninjurin1-24 variant regulating hypertro-
phy and myogenesis. Ninjurin1-16 and Ninjurin1-24 showed distinct subcellular localizations
suggesting that Ninjurin1 depending on its modification has additional functions aside from
its well described role as cell surface and adhesion molecule. Collectively our results suggest
that Ninjurin1 plays an important role in myocyte growth and differentiation.
Cardiac hypertrophy requires an increase in cell-cell and cell-matrix
contacts
Within the myocardium of the adult heart cardiomyocytes physically interact with each other
as well as with non-cardiomyocytes to form an intact syncytium. During pathological cardiac
hypertrophy the composition of the myocardium is dramatically altered by cardiomyocyte
growth [34], fibroblast activation, deposition of extracellular matrix proteins, and neovascular-
ization [35]. To nevertheless assure a proper mechanical and electro-mechanical coupling and
to withstand increased cardiac workload, hypertrophied myocytes have to be functionally
embedded in the myocardial syncytium [36]. Therefore cell-cell and cell-matrix interactions,
500 μm. (D) Western blots of proteins isolated from C2C12 myoblasts, and 7 days differentiated myotubes, treated with cycloheximide (CHX) and MG132 for
different time points, as indicated, with anti-Ninjurin1, Myogenin and Herp antibody (as indicated). GAPDH was used as loading control.
https://doi.org/10.1371/journal.pone.0216987.g006
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Fig 7. Ninjurin1 deficiency impairs zebrafish heart and skeletal muscle development. Zebrafish (wild type or
transgenic Tg(myl7:EGFP)twu34) embryos were injected with ribonucleoprotein complex of Cas9 and sgRNA targeting
exon 1 of ninjurin1 (ninj1 sgRNA) or morpholino targeting exon2/intron2 junction of ninjurin1 (ninj1e2i2 MO) at one
cell stage and compared to uninjected control. In all panels, embryos were analysed at 48–50 hours post fertilization
(hpf). (A) Representative images of uninjected controls and ninjurin1-deficient embryos showing cardiac and body
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mediated by cell surface proteins, increase [37]. We found that Ninjurin1 was expressed in car-
diomyocytes and upregulated during pathological cardiac hypertrophy in both patients and
mice. Only few cell adhesion molecules, such as β-1D integrin [38], neural cell adhesion mole-
cule (NCAM) [6], and intercellular adhesion molecule-1 (ICAM-1) [5] are involved in cardiac
hypertrophy. For example, integrins are membrane-spanning proteins that connect the sarco-
mere to the extracellular matrix and regulate intracellular signaling pathways. Overexpression
of integrin β-1D, a muscle-specific isoform, augments the hypertrophic response induced by
α1 adrenergic stimulation in neonatal cardiomyocytes in vitro [38]. Importantly, integrins
activate Akt and mitogen-activated protein kinase signaling pathways, which control the
hypertrophic response of cardiomyocytes [39]. Like integrins, Ninjurin1 was also described as
cell-surface protein mediating cell-cell interactions [7] and could thus be involved in myocyte
growth and mediate pathological cardiac hypertrophy. Thus far, no data about Ninjurin1‘s
mediated signaling processes in myocytes are available. However, our finding that loss on Nin-
jurin1 reduces the hypertrophic response of NRVM and H9c2 cells indicates that Ninjurin1 is
involved in hypertrophic signaling in vitro. In endothelial cells, Ninjurin1 was demonstrated
to modulate p38 and activator protein 1 activity [40], and p53-dependent cell proliferation and
apoptosis in vitro and in vivo [41]. Further studies are needed to investigate if Ninjurin1 acti-
vates one of these or other signaling pathways in myocytes.
We found that in myocardium, Ninjurin1 expression was low at baseline but strongly
increased in cardiac hypertrophy. Interestingly, basal expression levels of Ninjurin1 in brain
and neurons were also low, but increased during development, inflammation and injury [7].
Given the prominent role of Ninjurin1 in inflammation [40] and nerve repair [7, 13, 14], tran-
scriptional regulation of Ninjurin1 seems to be important for its function. As Ninjurin1, also
NCAM increases in the myocardium after heart transplantation [6] and ICAM increases dur-
ing enhanced work load [5]. Collectively, reported and our own data indicate that increased
Ninjurin1 expression is a prerequisite for its function in myocyte hypertrophy.
Role of Ninjurin1 for cardiac development
We observed inhibition of cardiac looping and dextrocardia in Ninjurin1 mutant zebrafish. To
our knowledge, this observation is the first in vivo demonstration of a functional significance
of Ninjurin1 during cardiogenesis. The crucial event of cardiac looping is tightly regulated and
requires multiple factors [42]. The knowledge of these factors is incomplete, but molecules
involved in cell adhesion are important, such as NCAM [6] that regulates cardiac morphogen-
esis. Interestingly, FISH analysis localized the human NINJURIN1 gene to chromosome
axis defects. Scale bar, 1 mm. (B) The relative occurrence of the cardiac phenotypes is depicted. (C) qRT-PCR of ninj1
cDNA from uninjected control, control morpholino injected (control MO), and ninje2i2 MO injected embryos at 50
hpf. In control MO injected embryos, the size of the ninj1 amplified fragment is 254 bp (empty arrowhead), whereas it
is approximately 350 bp in ninj1 morphants, due to defective splicing of intron 2 (full arrowhead). (D) Panel plot
showing allele variations in ninj1 sgRNA-Cas9-injected embryos compared to the WT ninj1 allele (no variant)
(ENSDARG000001036663.1). (E) Relative mRNA expression of the ninj1 gene in uninjected, Cas9, and ninj1 sgRNA-
Cas9-injected embryos by qRT-PCR and normalized to eef1α1l mRNA expression. Data represent the log2 fold change
of ninj1. Cas9 to uninjected control, ns, P = 0.0686, ninj1 sgRNA-Cas9-injected embryos to uninjected controls, ��,
P = 0.0025. (F) Representative images of Tg(myl7:EGFP)twu34 showing defects in cardiac looping and dextrocardia in
ninj1-deficient embryos. Scale bar, 1 mm. (G) Quantification of the looping angle, ninj1 sgRNA-Cas9-injected embryos
to uninjected control, ��, P = 0.0012. (H) Heart rate remained unchanged in ninj1-deficient embryos; ninj1 sgRNA-
Cas9-injected embryos to uninjected control, ns, P = 0.8406. (I) Single confocal plane of whole-mount embryos
showing skeletal muscle cells and their nuclei stained with anti-myosin heavy chain antibody (mf20) and DAPI,
respectively. Myosin assembles within the sarcomeres in controls, while it forms aggregates in ninj1-deficient embryos
(in insets, apical section). Somites do not display the typical chevron shape, red line. Scale bar, 20 μm. (J) Somite length
was significantly shorter in ninj1-deficient embryos compared to controls; ��, P = 0.0025.
https://doi.org/10.1371/journal.pone.0216987.g007
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9q22.1-q22.3 [7]. A linkage analysis of patients with familial dilated cardiomyopathy identified
a putative disease locus at chromosome 9q13-q22 [43]. Together with our results, it is possible
that Ninjurin1 is a disease gene for dilated cardiomyopathy. Nevertheless, the precise role of
Ninjurin1 in cardiac morphogenesis needs further investigation.
Role of Ninjurin1 in myogenesis
We found that Ninjurin1 protein was expressed as a Ninjurin1-16 and Ninjurin1-24 variant.
Both forms were differentially expressed in a cell, tissue and condition dependent manner. By
using tunicamycin-induced inhibition we showed that Ninjurin1 was N-glycosylated (Nin-
jurin1-24). N-glycosylation is a major post-translational modification of proteins in eukaryotic
cells that influences the physicochemical and biological properties of proteins, such as protein
stability and dynamics, as well as cell–matrix and cell–cell interactions [44, 45]. The impor-
tance of N-glycosylation is demonstrated by the fact that its complete absence is embryonically
lethal [46]. In addition, genetic defects that affect protein glycosylation are associated with var-
ious human diseases [47]. Since Ninjurin1 was described as a cell surface protein, our observa-
tion is in line with the notion that N-linked glycosylation is a hallmark of cell membrane and
extracellular proteins [20]. For example, N-glycosylation influences the subcellular localization
and stability of various cell adhesion molecules, such as E- and N-cadherin [48] and integrins
[49] where it affects intercellular signal transduction and cell–cell adhesion. In fact, N-glycosyl-
ation of Ninjurin1 was recently described by Bae et al. to be important for its oligomerization
[15]. To these data, we add that N-glycosylation of Ninjurin1 in myocytes affects its stability
and its subcellular localization. Our results that N-glycosylation of Ninjurin1 (Ninjurin1-24)
primarily occurs during myogenic differentiation and myocyte and cardiac hypertrophy, and
decreases during myocyte atrophy together with the observation of Bae et al. implicate that N-
glycosylation of Ninjurin1 is important for myocyte growth and muscular adaptation during
pathological stress. Our findings that Ninjurin1-24 has a shorter half-life in cycloheximide
chase experiments and is primarily targeted by siRNA treatment when compared to Nin-
jurin1-16 suggests that N-glycosylation of Ninjurin1 reduces its stability, which is in line with
the effects of N-glycosylation for other membrane proteins, such as E- and N-cadherin and
integrins [48, 49]. Cell-cell adhesion is a prerequisite for myogenic differentiation. Absence of
myogenic differentiation in myoblasts devoid of N-glycosylated Ninjurin1 argues for its func-
tion in this process. This was further supported by our result that Ninjurin1-24 was exclusively
detected in differentiating myocytes, increased during hypertrophy and decreased during atro-
phy; whereas Ninjurin1-16 was continuously expressed in myoblasts, and differentiating and
atrophying myotubes. The hypothesis that Ninjurin1 participates in myogenic differentiation
was also supported by our observation that reduction of Ninjurin1 decreased and overexpres-
sion of Ninjurin1 increased the expression of the contractile protein myosin heavy chain,
which is essential for myocyte development, growth and function, and used as a marker for
myogenic differentiation [30]. Since Ninjurin1 specific siRNA abolished myogenic differentia-
tion and predominantly reduced Ninjurin1-24 but not Ninjurin1-16 we believe that myogenic
differentiation is primarily regulated by N-glycosylated Ninjurin1 (Ninjurin1-24).
Ninjurin1 was described as cell surface protein in non-myocytes [7, 8]. We show that in
myocytes, Ninjurin1 was not exclusively localized to the cell surface but also in the cytoplasm.
With fractionation assays we separated both Ninjurin1 variants; Ninjurin1-16 was primarily
found in the cytoplasm whereas Ninjurin1-24, as it was reported for other glycoproteins, dis-
tributed to membranous fractions. In myoblasts Ninjurin1-16 co-localized with α-actinin,
which is involved in assembly of myofibers and localizes to cell extensions and focal adhesions
in C2C12 myoblasts [50]. In summary, our data indicate that Ninjurin1-16 is possibly involved
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in migration and fusion of myocytes while Ninjurin1-24 mainly executes more myocyte spe-
cific functions, such as mediating myogenic differentiation and myocyte growth.
Conclusion
We conclude that Ninjurin1 is a multifunctional cell adhesion glycoprotein, which plays a role
in myocyte hypertrophy and myogenesis. Depletion of Ninjurin1 in zebrafish impairs striated
muscle development. To earlier observations that showed that Ninjurin1 is involved in nerve
repair, inflammation and cancer progression, we add that Ninjurin1 has important functions
during muscle homeostasis. Further analyses need to decipher specific signaling pathways
downstream of Ninjurin1 in myocytes.
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S1 Fig. Ninjurin1 is increased in hypertrophic left ventricle of patients. Western blots of
proteins isolated from left ventricular tissue of patients with severe aortic stenosis (AS) under-
going elective aortic valve replacement surgery (n = 9) and donor hearts (n = 6) using anti-
Ninjurin1 antibody. Tubulin and GAPDH were used as loading controls. The Ninjurin1 iso-
forms at 16kDa (Ninjurin1-16) and 24kDa (Ninjurin1-24) are differentially expressed there-
fore the membranes underwent short and long exposure, indicated by short exp. and long
exp., respectively.
(EPS)
S2 Fig. Ninjurin1-16 and Ninjurin1-24 distribute to distinct cytoplasmic fractions of myo-
cytes. (A) Immunofluorescent staining of C2C12 myoblasts with anti-Ninjurin1 and anti-α-
actinin as primary antibody, and Alexa Fluor 488 (green) and Alexa Fluor 555 (red) conjugated
secondary antibody, respectively. Nuclei were stained with DAPI (blue). Scale bar, 75 μm.
Inset (red box) is enlarged beside the panel. The arrow indicates stress fibers. (B) Immunofluo-
rescent staining of C2C12 myoblasts and 5 days differentiated myotubes with anti-Ninjurin1
and anti-GAPDH as primary antibody, and Alexa Fluor 488 (green) and Alexa Fluor 555 (red)
conjugated secondary antibody, respectively. Nuclei were stained with DAPI (blue). Scale bar,
75 μm. (C) C2C12 myoblasts and myotubes were subjected to biochemical cell fractionation.
Proteins of each fraction were separated by SDS-PAGE and immunoblotted using anti-Nin-
jurin1, anti-AIF or anti- GAPDH antibody. The 16kDa (Ninjurin1-16) and 24kDa (Ninjurin1-
24) Ninjurin1 isoforms are indicated. C indicates cytoplasmatic, M membranous, N nuclear,
C1 cytosolic, M1 vesicular fractions, respectively.
(EPS)
S3 Fig. Overexpression of Ninjurin1 accelerates differentiation of C2C12 myocytes. C2C12
myoblasts were transfected with cDNA expression plasmids encoding Flag-Ninjurin1 (n = 12)
or empty vector control (Control) (n = 12). Differentiation was induced 24 hours post-trans-
fection. Samples for RNA and protein isolation were obtained from myoblasts (0) and after 3,
5 and 7 days of differentiation as indicated. Three samples per group were analyzed (n = 3).
(A) Western blots of proteins isolated from C2C12 myoblasts, and for 3, 5 and 7 days differen-
tiated myotubes, as indicated (MT3, MT5, MT7), with anti-slow myosin, anti-fast myosin and
anti-FLAG antibody (Flag-Ninjurin1) as indicated. GAPDH was used as loading control. A
two-tailed, unpaired Student’s t-test was used to calculate the P values. (B) qRT-PCR analysis
of myosin heavy chain (MyH) 1, 2, 4 and 7. Glyceraldehyde-3 phosphate dehydrogenase
(GAPDH) expression was used as reference. Data are presented as mean ± SD. � P < 0.05,
�� P< 0.01, § P< 0.001 compared to myoblast control.
(EPS)
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